Does Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Contribute to Impairment of Fibrinolysis in Patients with Preeclampsia and/or Intrauterine Fetal Growth Retardation?

Summary

Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a relatively recently described glycoprotein (MM 55 KDa) that can be converted into its active form by the thrombin/thrombomodulin complex and potentially inhibits fibrinolysis. Since it represents a link between coagulation and fibrinolysis, TAFI can be expected to play a part in various clinical conditions associated with a thrombotic tendency. Preeclampsia (PE) and intrauterine fetal growth retardation (IUFGR) are fairly common complications of pregnancy that are characterized by hemostatic abnormalities. TAFI antigen and its influence on hemostasis was investigated in 46 women with PE and/or IUFGR and in 16 normal pregnancies. We found a significant decrease of TAFI antigen in the patient group. Using the recently described method Overall Hemostatic Potential (OHP) in plasma, we measured clot lysis time (CLT) and overall fibrinolytic potential (OFP). We found that CLT is prolonged and OFP decreased in patients with PE and/or IUFGR. Since OFP did not increase after addition of the specific inhibitor of TAFI (potato tuber carboxypeptidase inhibitor), it seems that TAFI does not contribute to the impairment of fibrinolysis in these patients. Since serum albumin was decreased together with presence of proteinuria and aminotransferases were increased in the patients, it seems that one explanation for the decrease in TAFI could be reduced hepatic synthesis and an increased loss in urine. It can be speculated that this mechanism can prevent more serious thrombotic complications in patients with PE and/or IUFGR.

Keywords

TAFI antigen - preeclampsia - overall fibrinolytic potential in plasma (OFP) - clotlysis time

• References

• 1 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
• 2 Bajzar L, Manuel R, Neisheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1477-84.
• 3 Bajzar L, Morser J, Neisheim ME. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
• 4 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
• 5 Wang W, Boffa MB, Bajzar L, Walker JB, Neisheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
• 6 Antovic J, Schulman S, Eelde A, Blomback M. Total thrombin activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with hemophilia A. Haemophilia 2001; 07: 557-60.
• 7 Van Thiei DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 667-70.
• 8 Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Strömqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
• 9 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk of deep vein thrombosis. Blood 2000; 95: 2855-9.
• 10 Meijers JCM, Oudijk EJD, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, Fijnheer R. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000; 108: 518-23.
• 11 Watanabe R, Wada H, Watanabe Y. et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104: 1-6.
• 12 Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902-5.
• 13 Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001; 115: 150-2.
• 14 Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53-6.
• 15 Perry Jr KG, Martin Jr JN. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clin Obstet Gynecol 1992; 35: 338-50.
• 16 Schjetlein R, Haugen G, Wisllow F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997; 76: 541-6.
• 17 Sheppard BL, Bonnar J. Uteroplacental hemostasis in intrauterine fetal growth retardation. Sem Thromb Hemost 1999; 25: 443-6.
• 18 Gilabert J, Estelles A, Grancha S, Espana F, Aznar J. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in preeclampsia. Hum Reprod 1995; 10 (Suppl. 02) 121-31.
• 19 He S, Bremme K, Blombäck M. Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preclampsia. Blood Coagul Fibrinolysis 1995; 06: 703-8.
• 20 Kanfer A, Bruch JF, Ngyen G. et al Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia. Lab Invest 1996; 74: 253-8.
• 21 He S, Antovic A, Blomback M. A Simple and Rapid Laboratory Method for Determination of Haemostasis Potential in Plasma II. Modifications for Use in Routine Laboratories and Research Work. Thromb Res 2001; 103: 355-61.
• 22 He S, Bremme K, Blomback M. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia. Blood Coagul Fibrinolysis 1997; 08: 232-8.